Abstract
Immune thrombocytopenia (ITP) is a syndrome characterized by low platelet counts and an increased risk of bleeding. For most children, ITP is a self-limiting disease; however, for some children and most adults, thrombocytopenia can become chronic. Newer therapies for ITP include rituximab and thrombopoietin (TPO) receptor agonists. Rituximab is a useful second-line therapy and may be splenectomy-sparing. Thrombopoeitin receptor agonists have demonstrated large treatment effects with respect to increasing platelet levels; however, they require maintenance dosing. This review summarizes how these new agents might be positioned in the management of patients with chronic ITP.
Copyright © 2012 Wiley Periodicals, Inc.
MeSH terms
-
Adult
-
Antibodies, Monoclonal, Murine-Derived / therapeutic use
-
Benzoates / therapeutic use
-
Blood Platelets
-
Child
-
Hemorrhage
-
Humans
-
Hydrazines / therapeutic use
-
Platelet Count*
-
Purpura, Thrombocytopenic, Idiopathic / immunology*
-
Purpura, Thrombocytopenic, Idiopathic / therapy*
-
Pyrazoles / therapeutic use
-
Receptors, Fc / therapeutic use
-
Receptors, Thrombopoietin / agonists
-
Recombinant Fusion Proteins / therapeutic use
-
Rituximab
-
Thrombopoiesis / drug effects*
-
Thrombopoiesis / immunology
-
Thrombopoietin / metabolism
-
Thrombopoietin / therapeutic use
Substances
-
Antibodies, Monoclonal, Murine-Derived
-
Benzoates
-
Hydrazines
-
Pyrazoles
-
Receptors, Fc
-
Receptors, Thrombopoietin
-
Recombinant Fusion Proteins
-
MPL protein, human
-
Rituximab
-
Thrombopoietin
-
romiplostim
-
eltrombopag